Galantos Pharma GmbH focuses on the development of drugs for the treatment of Alzheimer's and other neurodegenerative diseases. It develops a drug for the treatment of mild-to-moderate Alzheimer's dementia. The company develops a technology platform that is suitable for screening and preclinical validation of drug candidates that are acting on cholinergic and other neuro-receptors and on various brain enzymes. The company was founded in 2005 and is based in Mainz, Germany.
Funding Rounds (1) - $5.7MUpdate
|Mar 3, 2015||PRWeb Sitemap - Alzheimer Disease Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com|
|May 12, 2010||pharmaasia.com - Galantos Pharma Raises Funds to Advance Alzheimer`s Dementia Strategy|
|May 10, 2010||OnBioVC - Galantos Pharma, GmbH: Series C $5.7MbyOnBioVC|